leisure time -WSS

leisure time

author：Wikipedia 2025-09-10 08:20:41 - browse：8754

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： FDA moves to stop vape shops from selling Elf Bar, Esco Bars

WSS

At Orexo, a ‘turning point’ for everything but digital health

Diversity in clinical trials starts with building trust, experts say

Group opposing PBM reform sets lobbying record

Cosmetics set for new safety regulation. Why the industry is on board

Key House panel plots a new health care package

AI can’t replace a physician’s gut feeling

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare to cover more brain scans for Alzheimer’s patients

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bird flu outbreak in cows is latest avian flu curveball

Affirmative action in medical school literally saved lives

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Drug repurposing or repositioning? The language matters

Diversity in clinical trials starts with building trust, experts say

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare to cover more brain scans for Alzheimer’s patients

knowledge

UnitedHealth financials solid despite Change Healthcare cyberattack

Cue Health's Covid

FDA approves RSV monoclonal antibody for infants, toddlers

Health care needs a new profession: neuroimaging counseling

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

knowledge

explore

hotspot

focus